Archive: 27/09/2019
New studies question whether novel anti-cancer drugs are worth their extra cost
Many new anti-cancer medicines add little value for patients compared to standard treatment and are rarely worth the extra cost, according to results of two studies investigating links between clinical benefit and pricing ...
Sep 27, 2019
Clinical trial to test potential new therapy for giant cell arteritis
An international, multicenter phase II clinical trial is evaluating the efficacy and safety of mavrilimumab co-administered with a 26-week corticosteroid taper in patients with giant cell arteritis (GCA). The study is sponsored ...
Sep 27, 2019